citalopram has been researched along with Disease Exacerbation in 14 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Suicidal ideation was more likely to occur early in citalopram treatment, with few subjects showing emergence or worsening occurring after 6 weeks of treatment." | 9.22 | Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. ( Bloch, MH; Coughlin, CG; Jakubovski, E, 2016) |
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI." | 9.17 | Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013) |
" The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 7.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
"Suicidal ideation was more likely to occur early in citalopram treatment, with few subjects showing emergence or worsening occurring after 6 weeks of treatment." | 5.22 | Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. ( Bloch, MH; Coughlin, CG; Jakubovski, E, 2016) |
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI." | 5.17 | Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013) |
" The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 3.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
"To test the hypothesis that the selective serotonin reuptake inhibitor (SSRI) citalopram would down-regulate human immunodeficiency virus (HIV) infectivity and that the greatest effects would be seen in people with depression." | 3.76 | Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. ( Benton, T; Blume, J; Douglas, SD; Dubé, B; Evans, DL; Gettes, DR; Lynch, K; Metzger, DS; Ping Lai, J; Tustin, NB, 2010) |
"Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2." | 2.76 | Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. ( Calugi, S; Cassano, GB; Fagiolini, A; Frank, E; Miniati, M; Rucci, P; Scocco, P, 2011) |
"The manifestations of daytime somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1)." | 1.36 | Excessive daytime somnolence in spinocerebellar ataxia type 1. ( Cunnington, D; Dang, D, 2010) |
"Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6." | 1.35 | Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. ( Alpert, JE; Fava, M; Fleck, J; Gilmer, WS; Gollan, JK; Howland, RH; Miyahara, S; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2008) |
"Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 9 (64.29) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Audley, GG | 1 |
Frankenfeld, P | 1 |
Dlamini, S | 1 |
Raubenheimer, P | 1 |
Hoare, J | 1 |
Cairncross, L | 1 |
Van den Berg, R | 1 |
Gule, MV | 1 |
Calligaro, G | 1 |
Kobayashi, M | 1 |
Kwak, MJ | 1 |
Aguilar, D | 1 |
Goyal, P | 1 |
Holmes, HM | 1 |
Deshmukh, AA | 1 |
Aparasu, RR | 1 |
Kelley, ME | 1 |
Dunlop, BW | 1 |
Nemeroff, CB | 1 |
Lori, A | 1 |
Carrillo-Roa, T | 1 |
Binder, EB | 1 |
Kutner, MH | 1 |
Rivera, VA | 1 |
Craighead, WE | 1 |
Mayberg, HS | 1 |
Jiang, W | 1 |
Velazquez, EJ | 1 |
Kuchibhatla, M | 1 |
Samad, Z | 1 |
Boyle, SH | 1 |
Kuhn, C | 1 |
Becker, RC | 1 |
Ortel, TL | 1 |
Williams, RB | 1 |
Rogers, JG | 1 |
O'Connor, C | 1 |
Choe, YM | 1 |
Kim, KW | 1 |
Jhoo, JH | 1 |
Ryu, SH | 1 |
Seo, EH | 1 |
Sohn, BK | 1 |
Byun, MS | 1 |
Bak, JH | 1 |
Lee, JM | 1 |
Yun, HJ | 1 |
Han, MI | 1 |
Woo, JI | 1 |
Lee, DY | 1 |
Coughlin, CG | 1 |
Jakubovski, E | 1 |
Bloch, MH | 1 |
Gilmer, WS | 2 |
Gollan, JK | 1 |
Wisniewski, SR | 3 |
Howland, RH | 1 |
Trivedi, MH | 3 |
Miyahara, S | 1 |
Fleck, J | 1 |
Thase, ME | 1 |
Alpert, JE | 1 |
Nierenberg, AA | 2 |
Warden, D | 2 |
Fava, M | 3 |
Rush, AJ | 3 |
Tosto, G | 1 |
Talarico, G | 1 |
Lenzi, GL | 1 |
Bruno, G | 1 |
Dang, D | 1 |
Cunnington, D | 1 |
Sacre, S | 1 |
Medghalchi, M | 1 |
Gregory, B | 1 |
Brennan, F | 1 |
Williams, R | 1 |
Benton, T | 1 |
Lynch, K | 1 |
Dubé, B | 1 |
Gettes, DR | 1 |
Tustin, NB | 1 |
Ping Lai, J | 1 |
Metzger, DS | 1 |
Blume, J | 1 |
Douglas, SD | 1 |
Evans, DL | 1 |
Rucci, P | 1 |
Frank, E | 1 |
Scocco, P | 1 |
Calugi, S | 1 |
Miniati, M | 1 |
Fagiolini, A | 1 |
Cassano, GB | 1 |
Zisook, S | 1 |
Sung, SC | 1 |
Haley, CL | 1 |
Chan, HN | 1 |
Balasubramani, GK | 1 |
Gaynes, BN | 2 |
Hollon, SD | 1 |
Spencer, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847] | Phase 4 | 127 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878] | Phase 3 | 90 participants (Actual) | Interventional | 2022-12-02 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6
Intervention | fmol/mg (Mean) |
---|---|
Escitalopram | 139.7 |
Placebo | 160.4 |
The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 7.4 |
Placebo | 7.0 |
hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 1.6 |
Placebo | 1.8 |
Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 9.9 |
Placebo | 10.3 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | percentage of change (Number) |
---|---|
Escitalopram | 45.8 |
Placebo | 52.5 |
"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks
Intervention | beats/minute (Mean) |
---|---|
Escitalopram | 6.34 |
Placebo | 9.1 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 11.4 |
Placebo | 12.2 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 19.3 |
Placebo | 23.6 |
Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 21.4 |
Placebo | 21.8 |
(NCT00574847)
Timeframe: Baseline to week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 71.9 |
Placebo | 44.4 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 34.2 |
Placebo | 17.5 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 66.1 |
Placebo | 83.9 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | nM (Mean) |
---|---|
Escitalopram | 4202.4 |
Placebo | 210.1 |
STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
Trait | State | |
Escitalopram | 31.2 | 27.9 |
Placebo | 32.0 | 29.5 |
1 review available for citalopram and Disease Exacerbation
Article | Year |
---|---|
The STAR*D study: treating depression in the real world.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Disease Progres | 2008 |
5 trials available for citalopram and Disease Exacerbation
Article | Year |
---|---|
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
Topics: Aged; Citalopram; Coronary Disease; Disease Progression; Double-Blind Method; Electrocardiography; E | 2013 |
Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Brain; Citalop | 2016 |
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Topics: Adult; Citalopram; Depressive Disorder, Major; Disease Progression; Female; Follow-Up Studies; Human | 2016 |
Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
Topics: Adult; Anxiety Disorders; Benzodiazepines; Citalopram; Combined Modality Therapy; Comorbidity; Depre | 2011 |
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Chronic Dis | 2012 |
8 other studies available for citalopram and Disease Exacerbation
Article | Year |
---|---|
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling; | 2020 |
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2021 |
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
Topics: Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cognitive Behavio | 2018 |
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
Topics: Adult; Chronic Disease; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistic | 2008 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
Excessive daytime somnolence in spinocerebellar ataxia type 1.
Topics: Activities of Daily Living; Amantadine; Ataxin-1; Ataxins; Brain Stem; Cerebellum; Citalopram; Dextr | 2010 |
Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; | 2010 |
Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD8-Positive T-Lymphocytes; Cell Line; Cells, Cultured; C | 2010 |